8
Oct
2024

Jiangsu Aidea Pharmaceutical Co., Ltd.

Exhibitor at CPHI Milan 2024 stand 4F8, API
About Us

Company Profile

Jiangsu Aidea Pharmaceutical Co., Ltd. ("Aidea Pharma", 688488.SH) was established in 2009 and listed on the Shanghai Stock Exchange STAR Market in 2020. As a high-tech pharmaceutical company, Aidea Pharma focuses on developing and marketing comprehensive anti-HIV/AIDS product portfolios while leveraging its competitive advantages in the research and production of human urine-derived proteins.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2022
    On CPHI since
  • 1
    Certificates
  • 500 - 999
    Employees
Company types
Distributor/Import Export
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 4F8, API

Products Featured at CPHI Milan 2024

  • Ulinastatin

    Product Ulinastatin

    1、A natural broad-spectrum proteinase inhibitor extracted from human urine

    2、Block the process of SIRS and MODS

    2、Protect the function of vital organs

  • Urokinase

    Product Urokinase

    1、A kind of zymoprotein extracted from human urine

    2、Activate the endogenous fibrinolysis system and convert plasminogen into plasmin

    3、Favorable ...

  • Sennae Folium Granule

    Product Sennae Folium Granule

    1、A natural botanical drug for the treatment of constipation recommended by the WGO* Guideline

    2、Purge heat, activate stagnation and relax Intestines

    3、An exclusive product with double sales channels of OTC & prescription

     

    *WGO: World Gas...
  • Ainuomiti Tablets (Anti-HIV/AIDS innovative drug)

    Product Ainuomiti Tablets (Anti-HIV/AIDS innovative drug)

    Ainuomiti Tablets 

    (Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets)

     

    The first innovative oral anti-HIV/AIDS single-tablet combination in China, containing key NCE of Ainuovirine.